Review Article
Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma
Table 1
Main targeted therapies currently in use for the treatment of medullary thyroid cancer.
| | | | Key targets | | http://www.clinicaltrials.gov/ | | |
Drug name | |
IC50 RET
M* | | | | RET | EGFR | VEGFRs | PDGFR | cKIT | FGFR | MET | BRAF | Other | | Drugs in combination | Status
identifier (phase) |
| | | Vandetanib
(ZD6474) | √ | √ | √ | √ | | | | | | 0.1 |
Bortezomib | Not yet recruiting:
NCT01661179 ()
Recruiting:
NCT00514046 ()
NCT01496313 (4)
Active, not recruiting, has results:
NCT00410761 (3)
NCT00358956 (2)
NCT00098345 (2)
Active, not recruiting:
NCT000923247 ()
NCT01298323 (3)
Withdrawn: | | | | | | | | | | | | | |
Docetaxel | NCT000937417 | | | XL184
(Cabozantinib) | √ | | √ | | √ | | √ | | √ | 0.004 | | Active, not recruiting:
NCT00704730 (3)
NCT00215605 (1)
Available:
NCT01683110 | | Main TKIs | Sorafenib (BAY-43-9006) | √ | | √ | √ | √ | √ | | √ | √ | 0.0059–0.05 | | Active, not recruiting:
NCT00390325 (2)
Unknown**:
NCT006542387 (2) | | | Sunitinib (SU11248) | √ | | √ | √ | √ | | | | √ | 0.22–1.3 | | Active, not recruiting:
NCT00381641 (2)
NCT00519896 (2)
NCT00510640 (2) | | | Motesanib
(AMG-706) | √ | | √ | √ | √ | | | | | 0.05–0.09 | | Completed:
NCT00121628 (2) | | | Imatinib
(STI571) | | | | √ | √ | | | | √ | 5–37 |
Xeloda, Dacarbazine | Active, not recruiting:
NCT00354523 () |
| | | Everolimus (RAD001) | mTOR
| |
Pasireotide
Pasireotide | Recruiting:
NCT01625520 (2)
NCT01270321 (2)
NCT01164176 (2)
Unknown**:
NCT0111865 (2) | | Main Non-TKIs | Bortezomib
(PS-341) | proteosome | |
Vandetanib | Active, not recruiting:
NCT00923247 ()
| | | Pasireotide
(SOM230) | sst1, 3, 5
(somatostatin receptors) | |
Everolimus
Everolimus | Recruiting:
NCT01625520 (2)
NCT01270321 (2) |
|
|
*IC50 RET [M]: 50% inhibitory concentration.
**Status has not been verified in more than two years.
|
